Sara Elizabeth Townsley

Array ( [id] => 19658458 [patent_doc_number] => 20240425523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => Compounds for the Degradation of EGFR Kinase [patent_app_type] => utility [patent_app_number] => 18/678898 [patent_app_country] => US [patent_app_date] => 2024-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18678898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19683913 [patent_doc_number] => 20250002458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => SALT FORMS OF NICORANDIL DERIVATIVE [patent_app_type] => utility [patent_app_number] => 18/672454 [patent_app_country] => US [patent_app_date] => 2024-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23507 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18672454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631107 [patent_doc_number] => 20240409556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => BENZOPIPERAZINE AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD [patent_app_type] => utility [patent_app_number] => 18/666159 [patent_app_country] => US [patent_app_date] => 2024-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90789 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18666159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20348463 [patent_doc_number] => 20250345315 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => Dispenseable formulation for active pharmaceutical ingredients [patent_app_type] => utility [patent_app_number] => 18/660279 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18660279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447224 [patent_doc_number] => 20240307354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METHOD FOR TREATING HEAD AND NECK CANCER [patent_app_type] => utility [patent_app_number] => 18/656947 [patent_app_country] => US [patent_app_date] => 2024-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403573 [patent_doc_number] => 20240287084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => SYNTHESIS OF [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINES [patent_app_type] => utility [patent_app_number] => 18/644781 [patent_app_country] => US [patent_app_date] => 2024-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18644781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20321317 [patent_doc_number] => 20250333405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => ANTAGONISTS OF GPR39 PROTEIN [patent_app_type] => utility [patent_app_number] => 18/645159 [patent_app_country] => US [patent_app_date] => 2024-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52593 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18645159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541659 [patent_doc_number] => 20240358695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => Pharmaceutical Compositions of Rimegepant [patent_app_type] => utility [patent_app_number] => 18/643177 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510512 [patent_doc_number] => 20240342198 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => TREATMENT OF IRRITABILITY IN SUBJECTS WITH AUTISM SPECTRUM DISORDERS WITH MODERATE TO SEVERE ANXIETY AND/OR SOCIAL AVOIDANCE [patent_app_type] => utility [patent_app_number] => 18/642059 [patent_app_country] => US [patent_app_date] => 2024-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18642059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464095 [patent_doc_number] => 20240317764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => SALTS AND SOLID FORMS OF A COMPOUND HAVING APJ RECEPTOR ACTIVITY [patent_app_type] => utility [patent_app_number] => 18/620951 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316764 [patent_doc_number] => 20240238304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => Small Molecule Degraders of DOT1L and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/512950 [patent_app_country] => US [patent_app_date] => 2023-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33431 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127159 [patent_doc_number] => 20240132512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT [patent_app_type] => utility [patent_app_number] => 18/377105 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18377105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186153 [patent_doc_number] => 20240165066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT [patent_app_type] => utility [patent_app_number] => 18/472875 [patent_app_country] => US [patent_app_date] => 2023-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18472875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097704 [patent_doc_number] => 20240116932 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => COCRYSTALLINE FORMS OF FGFR3 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/462286 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16284 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922903 [patent_doc_number] => 20240025907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => QUINAZOLINE PAN-KRas INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/229662 [patent_app_country] => US [patent_app_date] => 2023-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96689 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18229662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18953538 [patent_doc_number] => 20240041865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/351439 [patent_app_country] => US [patent_app_date] => 2023-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18351439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18738046 [patent_doc_number] => 20230346955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/140863 [patent_app_country] => US [patent_app_date] => 2023-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18140863 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496381 [patent_doc_number] => 20240335399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => PHENYLEPHRINE HYDROCHLORIDE-CONTAINING TABLET, PREPARATION METHOD AND USE [patent_app_type] => utility [patent_app_number] => 18/271188 [patent_app_country] => US [patent_app_date] => 2023-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18271188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808576 [patent_doc_number] => 20230382910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN [patent_app_type] => utility [patent_app_number] => 18/305186 [patent_app_country] => US [patent_app_date] => 2023-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 133981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18305186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879011 [patent_doc_number] => 20240002380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => REV-ERB AGONISTS [patent_app_type] => utility [patent_app_number] => 18/134055 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18134055 [rel_patent_id] =>[rel_patent_doc_number] =>)